EUVIMEDEUVIMED entdecken
Crossref

First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy

Zhen Qiao, Shen Li, Yongzhong Zhang, Xiaobin Zhao iD, Zihao Yang, Xinyu Sun, Hualong Chen, Xuebo Cheng, Yajing Liu, Lin Ai, Zehui Wu iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.6c01052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Zhen Qiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing100071, China. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Epilepsy, Nerve Tissue Proteins, Membrane Glycoproteins. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Capital Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the first-in-human evaluation of [18F]BIBD-181, a novel SV2A tracer designed with a fluoropropyl side chain to enable mild, automated radiosynthesis. A fully automated cGMP-compliant production process was developed on a commercial synthesizer, yielding the tracer with >95% radiochemical purity and molar activity >130 GBq/μmol. In eight healthy volunteers, [18F]BIBD-181 demonstrated excellent safety, rapid brain penetration peaking at 15 s post-injection, and a regional uptake pattern consistent with known synaptic vesicle glycoprotein 2A (SV2A) distribution (pallidum SUV = 2.01 ± 0.57 at 30 min). The effective dose was 2.7 μSv/MBq, with predominant renal clearance and no detectable defluorination. In pilot epilepsy patients, [18F]BIBD-181 positron emission tomography (PET) results revealed focal SV2A reductions that were confined to the epileptogenic lesionsa sclerotic hippocampus in one patient and a focal cortical dysplasia (FCD) in anotherwhereas [18F]FDG showed either extensive ipsilateral temporal hypometabolism or concordant focal hypometabolism, suggesting that SV2A imaging may offer more precise lesion delineation, particularly when [18F]FDG abnormalities extend beyond the true epileptogenic zone. These findings establish [18F]BIBD-181 as a clinically practical SV2A PET tracer with favorable dosimetry, simplified production, and promising utility for epilepsy surgical planning, warranting further validation in larger cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyEpilepsyNerve Tissue ProteinsMembrane GlycoproteinsFluorine RadioisotopesRadiopharmaceuticalsHumansMaleFemaleTissue DistributionAdultBrainRadiometryYoung AdultMiddle Aged

Stichwörter der Autor:innen

PET imagingSV2A[18F]BIBD-181automated radiosynthesisdosimetryepilepsy

Substanzen

SV2A protein, humanNerve Tissue ProteinsMembrane GlycoproteinsFluorine RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing100071, China.
  • Beijing Institute of Brain Disorders, Beijing Key Laboratory of Innovation and Translation of Central Nervous System Radiopharmaceuticals, Capital Medical University, Beijing100069, China.
  • School of Pharmaceutical Science, Capital Medical University, Beijing100069, China.

ORCID-Profile: Xiaobin Zhao, Zehui Wu

Förderung

  • Natural Science Foundation of Beijing Municipality
  • Capital Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Qiao, Z., Li, S., Zhang, Y., Zhao, X., Yang, Z., Sun, X., Chen, H., Cheng, X., Liu, Y., Ai, L., & Wu, Z. (2026). First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c01052

Vancouver

Qiao Z, Li S, Zhang Y, Zhao X, Yang Z, Sun X, et al. First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c01052

BibTeX
@article{Qiao2026,
  author = {Qiao, Zhen and Li, Shen and Zhang, Yongzhong and Zhao, Xiaobin and Yang, Zihao and Sun, Xinyu and Chen, Hualong and Cheng, Xuebo and Liu, Yajing and Ai, Lin and Wu, Zehui},
  title = {First-In-Human PET Imaging of Synaptic Vesicle Glycoprotein 2A with [18F]BIBD-181: Automation, Biodistribution, Dosimetry, and Preliminary Application in Epilepsy},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c01052}
}
Kostenlos starten →